We must note that the selection of CD19-positive cells may only reflect a subset of the B-cell population, as exemplified by the emergence of tumor escape variants with B-cell antigen loss (e.g. CD19) in relapsed disease [57]. This evidence concerns the gene CD19 and neoplasm.